Polyamide Compounds Targeting TGGAA Repeats for SCA31 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Spinocerebellar ataxia type 31 (SCA31) is a neurodegenerative disease caused by the expansion of TGGAA repeats in the bean gene, leading to progressive cerebellar ataxia with no effective treatment available, as existing methods fail to modulate the expression of the defective gene effectively.
Innovation Solution
Development of chimeric heterocyclic polyamide compounds that selectively bind to the TGGAA pentanucleotide repeat sequence of the bean gene, recruiting regulatory molecules to modulate gene expression and reduce the production of toxic mRNA, thereby alleviating the symptoms of SCA31.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatment methods are used, then the disease progression cannot be halted, but the complexity of treatment protocols increases without effective results
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bridge the gap between the defective bean gene and regulatory molecules. These compounds selectively bind to the TGGAA repeat sequence and recruit regulatory molecules to modulate gene expression, providing a simple yet effective treatment mechanism that resolves the contradiction between treatment effectiveness and protocol complexity
2Object-generated harmful factors
If the bean gene expression is not modulated, then toxic mRNA continues to be produced, but no effective intervention method exists
Solution Approach 1:
The patent extracts the problematic TGGAA repeat sequence as a specific target and designs compounds that selectively bind to this sequence. By taking out the defective region as the focal point of intervention, the invention enables specific modulation of bean gene expression to reduce toxic mRNA production, addressing both the harmful factor and the lack of treatment options
3Measurement precision
If selective binding to TGGAA repeats is achieved, then gene expression can be modulated, but the compound must show high specificity among many DNA sequences
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that match the local characteristics of the TGGAA repeat sequence. The compounds contain functional groups and molecular arrangements that are optimized for binding to this specific pentanucleotide sequence, achieving high binding specificity without requiring overly complex overall structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyamide compounds effectively bind to the TGGAA repeats, recruiting regulatory molecules to the bean gene, thereby downregulating its expression, providing a promising treatment for SCA31 by reducing the occurrence and severity of symptoms.
Implementation Method 1
The compounds disclosed herein contain: (a) a recruiting moiety that will bind to a regulatory molecule, linked to (b) a DNA binding moiety that will selectively bind to bean
Data Source
AI summary
The present disclosure relates to compounds and methods for modulating the expression of bean (brain expressed, associated with NEDD4) and treating diseases and conditions in which bean plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence TGGAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence TGGAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.